Journal of Cardiac Failure
Volume 14, Issue 6 , Pages 445-452 , August 2008

Pioglitazone and Heart Failure: Results From a Controlled Study in Patients With Type 2 Diabetes Mellitus and Systolic Dysfunction

  • Thomas D. Giles, MD

      Affiliations

    • Tulane University School of Medicine, New Orleans, Louisiana
    • Corresponding Author InformationReprint requests: Thomas Giles, MD, Professor of Medicine, Tulane University School of Medicine, 109 Holly Drive, Metairie, LA 70005.
    • ,
  • Alan B. Miller, MD

      Affiliations

    • University of Florida Health Science Center, Jacksonville, Florida
    • ,
  • Uri Elkayam, MD

      Affiliations

    • University of Southern California Keck School of Medicine, Los Angeles, California
    • ,
  • Mondira Bhattacharya, MD

      Affiliations

    • Takeda Global Research & Development Center, Inc, Deerfield, Illinois
    • ,
  • Alfonso Perez, MD

      Affiliations

    • Takeda Global Research & Development Center, Inc, Deerfield, Illinois

Received 27 August 2007 ,Revised 22 January 2008 ,Accepted 5 February 2008.

References 

  1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234
  2. Nichols GA, Gullion CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes. Diabetes Care. 2004;27:1879–1884
  3. Reavan G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation. 2002;106:286–288
  4. ACTOS prescribing information. Takeda Pharmaceuticals America, Inc; 2007;
  5. Avandia prescribing information. GlaxoSmithKline; 2007;
  6. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention. PNAS. 2005;102:9406–9411
  7. Guan YF, Hao C, Cha DR, Rao R, Lu W, Kohan DE, et al. Thiazolidinediones expand body fluid volume through PPARγstimulation of ENaC-mediated renal salt absorption. Nature Medicine. 2005;11:861–866
  8. Dargie HJ, Hildebrandt PR, Riegger GAJ, McMurray JJV, McMorn SO, Roberts JN, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol. 2007;49:1696–1704
  9. Giles TD, Miller AB, Elkayam U, Bhattacharya M, Perez A. Preserving systolic function: two studies demonstrate safety of pioglitazone in patients with type 2 diabetes mellitus and heart failure. J Am Coll Cardiol. 2007;49(Suppl A):66A
  10. Maru S, Koch GG, Stender M, Clark D, Gibowski L, Petri H, et al. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Care. 2005;28:20–26
  11. Derosa G, Cicero AF, Dangelo A, Gaddi A, Ragonesi PD, Piccinni MN, et al. Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res. 2005;28:917–924
  12. Basu A, Jensen MD, McCann F, Mukhopadhyay D, Joyner MJ, Rizza RA. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care. 2006;29:510–514
  13. Dormandy JA, Charbonnel B, Eckland DJA, Erdmandn E, Massi-Benedetti M, Moules I, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events). Lancet. 2005;366:279–289
  14. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM. on behalf of the PROactive investigators. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction—Results from PROactive (PROactive 05). J Amer Coll Cardiol. 2007;49:1772–1780
  15. Wilcox R, Bousser M-G, Pirag V, Betteridge J, Schernthaner G, Kupfer S, et al. PROactive 04: Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke—results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events). Stroke. 2007;38:865–873
  16. Rydén L, Thráinsdóttir I, Swedberg K. Adjudication of serious heart failure in patients from PROactive. [letter] Lancet. 2007;368:189–190
  17. Erdmann E, Standl E, Charbonnel B, Wilcox R, Spanheimer R, Massi-Benedetti M, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007;30:2773–2778
  18. Lincoff MA, Wolski K, Nicholls SJ, Nissen S. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2007;298:1180–1188
  19. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471
  20. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547–1554
  21. Berhanu P, Kipnes MS, Khan MA, Perez AT, Kupfer SF, Spanheimer RC, et al. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res. 2006;3:39–44
  22. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28:2345–2351
  23. American Diabetes Association . Standards of medical care in diabetes. Diabetes Care. 2008;31:S12–S54

 Sponsored and funded by Takeda Global Research & Development Center, Inc. Deerfield, Illinois.

 Partial data from this study have been published previously as congress abstracts (American College of Cardiology Scientific Session 2007 and European Society of Cardiology Congress 2007).

 Dr. Thomas Giles has received honoraria for speaking/consulting services and research grants from Takeda Pharmaceuticals; Dr. Allen Miller has received honoraria for speaking services from Takeda Pharmaceuticals and payment from GlaxoSmithKline for consulting services; Dr. Uri Elkayam has received honoraria for speaking/consulting services and research grants from Takeda Pharmaceuticals; Drs. Perez and Bhattacharyra are employees of Takeda Pharmaceuticals.

 Funded by Takeda Pharmaceuticals (Takeda Global Research & Development).

PII: S1071-9164(08)00060-2

doi: 10.1016/j.cardfail.2008.02.007

Journal of Cardiac Failure
Volume 14, Issue 6 , Pages 445-452 , August 2008

Article Tools

* Image Usage & Resolution